OHI指数预测淋巴瘤患者器官功能障碍导致的早期死亡及依托泊苷的生存获益
这项多中心回顾性研究纳入135例新诊断淋巴瘤患者(70例OHI阴性、65例OHI阳性),评估OHI指数与死亡原因及生存的关系。OHI阳性患者1年总生存率显著低于OHI阴性患者(33% vs 81%,P < .0001),死亡风险增加13倍(比值比13.3;95%置信区间6.0-28.5),死亡主要归因于多器官衰竭而非淋巴瘤进展;在OHI阳性T细胞淋巴瘤中,将依托泊苷纳入淋巴瘤导向治疗与总生存改善相关(P = .007)。
要点
- OHI阳性淋巴瘤患者1年总生存率33% vs OHI阴性81%(P < .0001),中位生存190天。
- OHI阳性患者死亡风险增加13倍(比值比13.3;95%置信区间6.0-28.5),58%死于多器官衰竭。
- OHI阳性T细胞淋巴瘤中,依托泊苷纳入治疗与总生存改善相关(P = .007)。
核心结论
- OHI指数可作为淋巴瘤的预后工具,有助于阐明死亡机制并识别可能从个体化治疗中获益的高危亚组。
研究设计与样本
- 多中心、回顾性研究,纳入135例新诊断淋巴瘤且有可用的可溶性CD25和铁蛋白检测结果的患者,分为OHI阳性65例与OHI阴性70例。
主要发现
- OHI阳性患者1年总生存率33% vs OHI阴性81%(P < .0001),中位生存190天。
- OHI阳性患者死亡风险增加13倍(比值比13.3;95%置信区间6.0-28.5),尽管基于常规指数的预测总生存相似(72% vs 65%;P = .46)。
- 58%的OHI阳性患者死于多器官衰竭,仅6%死于淋巴瘤进展;而43%的OHI阴性患者死于淋巴瘤进展。
- 在OHI阳性T细胞淋巴瘤中,将依托泊苷纳入淋巴瘤导向治疗与总生存改善相关(P = .007)。
关键数值与推荐
- OHI指数基于可溶性CD25(>3900 U/mL)和铁蛋白(1000 ng/mL)水平的联合升高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hemophagocytic lymphohistiocytosis (HLH) is a hyperinflammatory syndrome that complicates hematologic malignancies. The Optimized HLH Inflammatory (OHI) index, based solely on the combined elevation of soluble CD25 (sCD25; >3900 U/mL) and ferritin (1000 ng/mL) levels, predicts mortality more effectively than the conventional HLH criteria. This study aimed to determine whether mortality in OHI-positive (OHI+) patients is primarily caused by lymphoma or inflammation-related causes. In a multicenter, retrospective study of patients with newly diagnosed lymphoma with sCD25 and ferritin measurements available, patients were classified as OHI+ or OHI negative (OHI-). The 1-year and 3-year overall survival (OS), event-free survival, and causes of death were analyzed, along with predicted vs observed mortality based on other lymphoma-relevant prognostic indexes. Among 135 patients with lymphoma (70 OHI- and 65 OHI+), OHI+ patients had significantly lower OS at 1 year (33% vs 81%; P < .0001) with a median survival of 190 days. OHI+ patients had a 13-fold increased mortality risk (odds ratio, 13.3; 95% confidence interval, 6.0-28.5) despite similar predicted OS based on conventional indexes (72% vs 65%; P = .46). Mortality causes differed significantly. A total of 58% of OHI+ patients died from multiorgan failure, whereas only 6% died from progressive lymphoma. In contrast, 43% of the OHI- patients died from lymphoma progression. The incorporation of etoposide into lymphoma-directed treatment was associated with improved OS in OHI+ T-cell lymphomas (P = .007). These findings underscore the clinical significance of the OHI index as a prognostic tool in lymphoma, to elucidate the mechanisms of mortality, and to identify a high-risk subgroup for which tailored treatments may lead to improved outcomes.
引用
- Zoref-Lorenz A, Murakami J, Gurion R, et al. The OHI index predicts early mortality from organ dysfunction and survival benefit from etoposide in patients with lymphoma. Blood Adv. 2025. PMID: 40249910. doi:10.1182/bloodadvances.2024014005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。